Lai Wang insider trades: BeOne Medicines (ONC) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Lai reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | ONC | ↓ Sell | 1,169 | $265.39 | $310K | Direct | Jun 18, 2026 (2d) |
| Jun 11, 2026 | ONC | ↓ Sell | 756 | $261.00 | $197K | Direct | Jun 15, 2026 (4d) |
| Jun 8, 2026 | ONC | ↓ Sell | 1,367 | $269.38 | $368K | Direct | Jun 10, 2026 (2d) |
| Sep 9, 2025 | ONC | ↓ Sell | 5,000 | $350.06 | $1.8M | Indirect | Sep 11, 2025 (2d) |
| Jul 30, 2025 | ONC | ↓ Sell | 4,300 | $302.65 | $1.3M | Indirect | Jul 31, 2025 (1d) |
| Jul 18, 2025 | ONC | ↓ Sell | 700 | $300.00 | $210K | Indirect | Jul 22, 2025 (4d) |
| Jun 23, 2025 | ONC | ↓ Sell | 1,028 | $260.00 | $267K | Direct | Jun 25, 2025 (2d) |
| Jun 17, 2025 | ONC | ↓ Sell | 1,647 | $262.11 | $432K | Direct | Jun 18, 2025 (1d) |
| Jun 6, 2025 | ONC | ↓ Sell | 1,402 | $252.39 | $354K | Direct | Jun 10, 2025 (4d) |
| Feb 21, 2025 | BGNE | ↓ Sell | 5,000 | $257.23 | $1.3M | Indirect | Feb 25, 2025 (4d) |
| Sep 27, 2024 | BGNE | ↓ Sell | 5,000 | $220.35 | $1.1M | Indirect | Oct 1, 2024 (4d) |
| Jun 24, 2024 | BGNE | ↓ Sell | 1,064 | $159.80 | $170K | Direct | Jun 26, 2024 (2d) |
| Jun 18, 2024 | BGNE | ↓ Sell | 2,341 | $157.27 | $368K | Direct | Jun 20, 2024 (2d) |
| Jun 26, 2023 | BGNE | ↓ Sell | 1,108 | $181.92 | $202K | Direct | Jun 27, 2023 (1d) |
| Jun 20, 2023 | BGNE | ↓ Sell | 1,325 | $192.42 | $255K | Direct | Jun 20, 2023 (0d) |
| Jun 7, 2023 | BGNE | ↓ Sell | 462 | $224.74 | $104K | Direct | Jun 9, 2023 (2d) |
| Jun 27, 2022 | BGNE | ↓ Sell | 458 | $177.32 | $81K | Direct | Jun 28, 2022 (1d) |
| Jun 21, 2022 | BGNE | ↓ Sell | 1,168 | $145.35 | $170K | Direct | Jun 22, 2022 (1d) |
| Jun 6, 2022 | BGNE | ↓ Sell | 660 | $142.00 | $94K | Direct | Jun 8, 2022 (2d) |
| Jun 28, 2021 | BGNE | ↓ Sell | 455 | $362.48 | $165K | Direct | Jun 30, 2021 (2d) |
| Jun 18, 2021 | BGNE | ↓ Sell | 802 | $331.15 | $266K | Direct | Jun 21, 2021 (3d) |
| Jun 7, 2021 | BGNE | ↓ Sell | 656 | $354.26 | $232K | Direct | Jun 9, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ONC insiders
Open-market trades in the last 12 months
About Lai Wang's insider trades
Lai Wang is President, Global Head of R&D at BeOne Medicines (ONC). Since Jun 7, 2021, Lai has reported no open-market purchases and 22 sales worth $9.7M on SEC Form 4. In the last 12 months: 3 sales ($876K).
Their filings also include grants and awards (10 filings), option exercises (1 filing), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.